Grants>Biomarkers

Requests for Applications: Biomarkers of Pancreatic Beta Cell Stress and Health

JDRF, the world’s leading non-profit organization with the mission to cure type 1 diabetes (T1D), invites applications from research investigators having interest and expertise to support the discovery and advancement of biomarkers of pancreatic beta cell stress and health correlating with early beta-cell loss.

The purpose of this call for Letters of Intent is to invite proposals to support and advance the discovery, development, and/or validation of biomarkers of pancreatic beta cell stress and dysfunction. Studies based on use or validation with human beta cells/islets and clinical samples or tissues will be of special interest.

MECHANISM

Applications in response to this announcement can be submitted under one of the following funding mechanisms:
Pilot & Feasibility Grants (P&Fs): up to $110,000 (including 10% indirect costs) for one year only.

Strategic Research Agreements (SRAs): Up to $250,000 USD per year including 10% indirect costs
for up to 3 years may be requested. The level of funding will vary depending on the scope and overall objectives of the proposal. Under the terms of the grant award, written quarterly (~2-3 pages) reports will be required from the funded investigator as a basis for continued support.

LETTER OF INTENT

Prospective applicants should submit a letter of intent on -line via the proposalCENTRAL website (https://proposalcentral.altum.com/default.asp).

The LOI template provided on the proposalCENTRAL Web site must be used to complete the application. Applicants will be notified approximately eight weeks after the LOI deadline date if they have been approved to submit a full application.

Letter of Intent Deadline: June 17, 2013.

2013 ASPIRE Rheumatology Research Awards

As competition for research funding increases, the ASPIRE program underscores Pfizer's commitment to supporting research in rheumatologic diseases.

Mission

The mission of the 2013 ASPIRE program is to support basic science, translational and clinical research through a competitive grants program that advances medical knowledge in the epidemiology, pathogenesis and treatment of selected diseases.

The ASPIRE Program demonstrates Pfizer’s commitment to supporting promising investigators with an interest in advancing knowledge in defined disease areas including rheumatologic diseases.

Scientific research continues to advance our knowledge and understanding of rheumatologic diseases. The 2013 ASPIRE Rheumatology Research Awards are designed to fund research proposals aimed to further the understanding of certain rheumatologic conditions and contribute to excellence in patient care.

Areas of Focus

Research areas of interest are as follows:

• Biomarker development/validation using patient-derived material

• Studies to improve diagnosis, prognosis or treatment

• Imaging in early diagnosis

• Imaging in treatment monitoring

• Patient-Reported Outcomes

• Impact of Discordance Between Patient and Physician Ratings of Disease Activity on Outcomes

Available Awards

Pfizer is funding research awards up to a maximum of $75,000 USD per-annum for up to 2 years (maximum total of an award over the 2 years of funding is $150,000).

Applicants

To be eligible for an award, applicants must:

• have a professional degree (MD, PhD, PharmD or equivalent)

• reside in the United States

Deadline for Application

• Applications must be received by July 1, 2013, 11:59pm EDST

• Addenda, supplemental materials, changes, or updates will not be accepted after the deadline

• Notification of Awards recipients will be in August 2013

How to Apply

Applications are to be submitted to Pfizer through an online submission website.

Request for Application: A-T Children's Project

Attention Researchers:

Request for Application (RFA) for March 1, 2013 and September 1, 2013

Seed funding is now available for innovative proposals that seek to identify and validate biomarkers of A-T disease progression and that can be used to monitor therapeutic efficacy in clinical trials.

Please note that investigator-initiated proposals are also welcome for the March 1 and September 1 grant submission deadlines; however priority will be given to proposals that address the above referenced RFA.

We welcome investigators to contact Cynthia Rothblum-Oviatt, PhD, our Science Coordinator, if help is needed forming collaborations and/or obtaining reagents for A-T/ATM research.

Cynthia Rothblum-Oviatt, PhD
Science Coordinator
A-T Children's Project
5300 W. Hillsboro Blvd., Suite 105
Coconut Creek, FL 33073
cynthia@atcp.org
Phone: 703-765-1223

International Rett Syndrome Foundation Translational Research Program

Cycle 2 Letter of Intent due:  July 1, 2013

IRSF announces the availability of HeART (Help Accelerate RTT Therapeutics) and ANGEL (Advanced Neurotherapeutic Grant of Excellence) grant awards to promote the development and testing of therapeutics to treat and reverse Rett syndrome (RTT) and its symptoms. These award mechanisms seek to facilitate the development and testing of novel therapeutics targeting the underlying pathology of the disorder, thereby leading to an amelioration of symptoms or ultimately a pharmacological reversal of RTT. Through these awards, IRSF seeks to foster academic and public-private partnerships and further facilitate drug discovery, development and testing.

IRSF encourages novel research programs that broadly encompass the following areas of unmet need:

Design, synthesis and testing of potential disease modifying therapeutics to treat or reverse RTT

Testing of existing therapeutics both in vitro and in vivo to repurpose their use in RTT

Development and/or validation of in vitro and in vivo models of RTT for therapeutic testing

Development and/or validation of novel biomarkers for objective clinical trials outcome measures

Testing of IND-ready therapeutics in pilot clinical trials

IRSF encourages investigators to utilize the newly available IRSF SMART Library of compounds in their proposed studies.

HeART (Help Accelerate RTT Therapeutics) Grant Award

Goal: To provide seed funding for early stage drug discovery and development efforts.

Funding: The maximum funding level for HeART grant awards is $150,000 for two years.

HeART grant awards are provided for cell-based assay development, early-stage drug discovery and development, early stage medicinal chemistry efforts on high value candidate therapeutics, cell-based screening of candidate therapeutics and follow-on early-stage in vivo testing. Grant applications for exploratory studies towards development of biomarkers or objective clinical outcome measures will also be considered.

ANGEL (Advanced Neurotherapeutic Grant of Excellence) Grant Award

Goal: To provide funding for the later stages of translational research.

Funding: The maximum funding level for ANGEL grant awards is $300,000 per year for up to two years.

Proposals must be comprised of very specific programs focused on pre-clinical drug discovery and development or clinical testing of therapeutic candidates. This mechanism requires development of a milestone based research plan, interim reporting on milestones and interaction with IRSF staff prior to and during the award period. The budget and duration of funding are variable and continued funding will be based on satisfactory progress on milestones. Applications are usually solicited, however, unsolicited proposals will be considered. Preliminary inquiries are required to determine IRSF’s level of interest prior to submission of an Expression of Interest (EOI).

Frequency:

Awards will be made in two cycles in 2013.

Please Note: IRSF requires all applicants to use our online submission process.

For application submission inquiries, please contact:

Janice Ascano, Ph.D. Manager of Grants and Research - jascano@rettsyndrome.org | 917-267-4504

For program related inquiries, please contact:

Steve Kaminsky, Ph.D., Chief Science Officer - skaminsky@rettsyndrome.org | 301-961-1559